World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
74
Citations
21271
World Ranking
1223
National Ranking
19

Overview

Peter Atadja is affiliated with Novartis in Switzerland and conducts research primarily within the fields of Biochemistry, Genetics and Molecular Biology, as well as Medicine. Their work spans several subfields, most notably Molecular Biology, Hematology, Oncology, Cell Biology, and Sociology and Political Science.

The main topics addressed in their research include:

  • Epigenetics and DNA Methylation
  • Protein Degradation and Inhibitors
  • Cancer-related gene regulation
  • Acute Myeloid Leukemia Research
  • RNA modifications and cancer
  • Peptidase Inhibition and Analysis
  • RNA Interference and Gene Delivery

Atadja has published multiple papers across several peer-reviewed journals. Notable recent publications include:

  • "Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies" (2022) in the Journal of Medicinal Chemistry
  • "Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction" (2023) in ACS Chemical Biology
  • "Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets" (2022) in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  • "Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia" (2020) in Clinical Epigenetics
  • "Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells" (2020) in Clinical Cancer Research

The frequent publication venues where Atadja's work appears include:

  • Clinical Cancer Research
  • Journal of Medicinal Chemistry
  • ACS Chemical Biology
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  • Clinical Epigenetics

The scientist collaborates regularly with a group of coauthors, including:

  • Kehao Zhao
  • Zhengtian Yu
  • Mengxi Zhao
  • En Li
  • Guo Li

Best Publications

  • High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

    Hui Gao;Joshua M Korn;Stéphane Ferretti;John E Monahan

  • Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS

    Purva Bali;Michael Pranpat;James Bradner;Maria Balasis

  • Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

    Unknown

  • Epigenetics in cancer: Targeting chromatin modifications

    Leigh Ellis;Peter W. Atadja;Ricky W. Johnstone

  • The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

    Alejandro Villagra;Fengdong Cheng;Hong Wei Wang;Ildelfonso Suarez

  • Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

    Unknown

  • Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

    Prince George;Purva Bali;Srinivas Annavarapu;Anna Scuto

  • Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells

    Ramadevi Nimmanapalli;Lianne Fuino;Purva Bali;Maura Gasparetto

  • Increased activity of p53 in senescing fibroblasts

    Peter Atadja;Howard Wong;Igor Garkavtsev;Claude Veillette

  • Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

    Warren Fiskus;Yongchao Wang;Arun Sreekumar;Kathleen M. Buckley

  • Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

    Lianne Fuino;Purva Bali;Sylvie Wittmann;Sreenivasa Donapaty

  • Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

    Fang Cao;Elizabeth C. Townsend;Hacer Karatas;Jing Xu

  • The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

    Patricia Maiso;Xonia Carvajal-Vergara;Enrique M. Ocio;Ricardo López-Pérez

  • Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells

    Fei Guo;Celia Sigua;Jianguo Tao;Purva Bali

  • Role of Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell Invasion

    Yonghua Yang;Rehka Rao;Jie Shen;Yun Tang

  • NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

    Laurence Catley;Ellen Weisberg;Yu-Tzu Tai;Peter Atadja

  • HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

    Rekha Rao;Warren C Fiskus;Yonghua Yang;Pearl Lee

  • Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

    Yongchao Wang;Warren Fiskus;Daniel G. Chong;Kathleen M. Buckley

  • Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy

    Yonghua Yang;Warren Fiskus;Bao Yong;Peter Atadja

  • N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

    Unknown

Frequent Co-Authors

Kapil N. Bhalla
Kapil N. Bhalla The University of Texas MD Anderson Cancer Center
Ricky W. Johnstone
Ricky W. Johnstone Peter MacCallum Cancer Centre
Karin Vanderkerken
Karin Vanderkerken Vrije Universiteit Brussel
Roberto Pili
Roberto Pili University at Buffalo, State University of New York
Karl Riabowol
Karl Riabowol University of Calgary
Amita Patnaik
Amita Patnaik University of Chicago
Jie Wu
Jie Wu Temple University
Ellen Weisberg
Ellen Weisberg Harvard University
Masoud Vedadi
Masoud Vedadi Structural Genomics Consortium
Cheryl H. Arrowsmith
Cheryl H. Arrowsmith Structural Genomics Consortium

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Molecular Biology opens the door to a wide range of online degrees and career opportunities. For students with a background in nursing, there are bsn to msn bridge programs that can help advance careers in healthcare and laboratory sciences, complementing skills in molecular techniques.

If you’re exploring academic options beyond traditional universities, consider enrolling in non profit online schools. These institutions often provide accredited, affordable, and flexible degree paths in science and related fields—ideal for working professionals or those seeking quality distance education.

For active-duty service members or veterans interested in the life sciences, there are online colleges for military. These schools offer military-friendly policies and support services to help you transition smoothly into a molecular biology career.

Additionally, students interested in integrating social impact with science may explore online msw programs. Social work professionals with a science background are in demand for roles in healthcare, public health, and community outreach.

Best Scientists Citing Peter Atadja

Trending Scientists

Recently Published Articles